AMENDMENT #1 TO MASTER CLINICAL STUDY AGREEMENT

This AMENDMENT #1 is entered into this 6th day of April, 2005, and amends the Master Clinical Study Agreement entered into by SmithKline Beecham Corporation, doing business as GlaxoSmithKline ("GSK") and one of the following component institutions ("Institution" and collectively "Institutions") of The University of Texas System ("System") located at 201 West 7th Street, Austin, Texas 78701, that is governed by its Board of Regents ("Board") as named in Exhibit B: The University of Texas Health Center at Tyler, The University of Texas Health Science Center at Houston, The University of Texas Health Science Center at San Antonio, The University of Texas M.D. Anderson Cancer Center, The University of Texas Medical Branch at Galveston, and The University of Texas Southwestern Medical Center at Dallas, which was effective the 10th day of November, 2003 ("Master Agreement").

Pursuant to the terms of the Master Agreement allowing for modification of the same, the parties hereby agree to replace Section 8, Publication, of the Master Agreement in its entirety as follows:

8. PUBLICATION

(a) Institution and Investigator agree that GSK may make public Study results from all Study sites, including, without limitation, by posting a summary of Study results in GSK’s online Clinical Trials Register before or after publication by any other method. In the event GSK coordinates a publication or presentation of Study results from all Study sites (a "Multicenter Publication"), the participation of Investigator or other representatives of Institution as a named author shall be determined in accordance with generally accepted standards for authorship. If the Investigator or other representative of Institution is a named author of the Multicenter Publication, such person shall have access to the Study data from all Study sites as necessary to fully participate in the development of the Multicenter Publication.

(b) Institution and Investigator, consistent with scientific standards and in a scientific forum, may publish or present the Study results from Institution’s Study data (an "Institution Publication"), provided that the Institution Publication does not also disclose any GSK Confidential Information other than the Study results from Institution’s Study data. Institution and Investigator shall submit to GSK for review and comment any proposed Institution Publication at least thirty (30) days prior to submitting the Institution Publication to any third party. If GSK requests a delay in order to file patent applications relating to an Invention, Institution agrees to and Investigator shall delay submitting the Institution Publication to any third party for up to sixty (60) days after GSK’s written request. Institution and Investigator also agree that any Institutional Publication shall only be made after the Multicenter Publication, provided that the Multicenter Publication is submitted within twelve (12) months after conclusion of the Study at Institution. If Multicenter Publication is not submitted within twelve (12) months after conclusion of the Study at Institution, Institution will be free to publish.

(c) The obligations of this Section shall survive termination of this Master Agreement and any applicable Study Specific Agreement.
If any provision of this Amendment #1 is inconsistent with the terms of the Master Agreement, the terms of this Amendment #1 shall prevail. Other than the modifications provided herein, the remaining terms of the Master Agreement remain in full force and effect.

IN WITNESS WHEREOF, the parties have acknowledged their consent to this Amendment #1 by executing it as of the day and year above written.

SMITHKLINE BEECHAM CORPORATION
d/b/a GLAXOSMITHKLINE

By: __________________________
Rosalind F. Cheetham
Vice President, North American Global Clinical Operations

Date: ____________

THE UNIVERSITY OF TEXAS HEALTH CENTER AT TYLER

By: __________________________
Rick Hefner
Vice President for Finance and Administration
Kirk A. Calhoun, M.D.
President

Date: ____________

THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON

By: __________________________
Kathryn A. Bradley
Senior Grants/Contracts Specialist
Catherine Moore
Director, Office of Sponsored Projects

Date: ____________

THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO

By: __________________________
Jane A. Youngers
Director, Grants Management

Date: ____________

THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER

By: __________________________
Leonard A. Zwieling, M.D., M.B.A.
Vice President, Research Administration
Melinda Mathis, MPA
Director, Sponsored Programs and Compliance

Date: ________________

THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON
By: Susan C. Ramsey

Date: 5/10/05

THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
By: Perrie M. Adams, Ph.D.
Associate Dean for Research

Date: 6/22/05